JERUSALEM--(BUSINESS WIRE)--Dec. 2, 2005--The Federal Trade Commission has notified Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Wyeth (NYSE:WYE) that it will not file an objection with the United States District Court for the District of New Jersey to the proposed settlement of the patent litigation between Teva and Wyeth concerning Teva’s application to market an extended release venlafaxine capsule product. Wyeth markets extended release venlafaxine under the tradename Effexor(R) XR.
